Ra Capital Management, L.P. bought $52.2M of Hemab Therapeutics (COAG)
Executed May 4, disclosed May 6, 2 days later.
Over the 21 trading sessions from the disclosed entry session (May 6), the stock returned +0.6% (delay-adjusted); from the execution session (May 4), -11.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Ra Capital Management, L.P. (Director) filed 31 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 22 priced purchase filings, the average 21-session return was +16.2% from execution and +14.2% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11.
Healthcare · Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of b…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→67,669 sh across 2 lots
Exec Jun 15
Filed Jun 17 · 6:24 PM ET COAGPURCHASE Hemab Therapeutics Holdings, Inc. $159K
6,387 sh × $24.90
Exec May 12
Filed May 14 · 5:21 PM ET COAGPURCHASE Hemab Therapeutics Holdings, Inc. $1.2M
47,790 sh across 3 lots
Exec May 7
Filed May 11 · 5:44 PM ET